Sensorion, a clinical-stage biotechnology company focused on therapies for hearing loss, will participate in the Association for Research in Otolaryngology (ARO) 49th Annual Midwinter Meeting held from February 7-11, 2026, in San Juan, Puerto Rico. Dr. Arnaud Giese, Group Leader for Animal Pharmacology at Sensorion, is scheduled to deliver a podium presentation on February 8, detailing the company’s gene therapy candidate SENS-601, aimed at treating autosomal recessive non-syndromic deafness (DFNB1A).
Sensorion specializes in developing novel treatments for inner ear disorders, including gene therapies targeting hereditary forms of deafness such as those caused by mutations in the OTOF and GJB2 genes. The company is also advancing clinical-stage small molecule therapies to prevent and treat hearing loss, with ongoing and completed Phase 2 studies in various hearing loss conditions.
**Why this matters**
Hearing loss affects millions worldwide, with limited effective treatments available for genetic forms of the condition. Sensorion’s research into gene therapies and small molecule drugs represents a significant effort to address these unmet medical needs. Presenting at a major scientific meeting like ARO allows the company to share progress with the research community and potentially accelerate the development of new hearing loss therapies.
Source: NewsData